替莫唑胺治疗弥漫性低级别胶质瘤患者的效果分析  

Efficacy of temozolomide for diffuse low-grade gliomas

作　　者：常浩[1] 徐德智[1] 张帅[1] 徐幸[1] 苗增利[1] 蔺玉昌[1] CHANG Hao XU De-zhi ZHANG Shuai XU Xing MIAO Zeng-li LIN Yu-chang(Department of Neurosurgery,Wuxi Second People＇s Hospital,Wuxi 214002, China)

机构地区：[1]江苏省无锡市第二人民医院神经外科,无锡214002

出　　处：《中国肿瘤临床与康复》2017年第5期522-524,共3页Chinese Journal of Clinical Oncology and Rehabilitation

基　　金：2012年国家自然科学基金青年科学基金项目(31200800)

摘　　要：目的探讨替莫唑胺治疗弥漫性低级别胶质瘤患者的效果。方法选取2007年1月至2008年9月间无锡市第二人民医院收治的96例弥漫性低级别胶质瘤患者,根据术后或放疗后是否进行替莫唑胺化疗将患者分为试验组(32例)与对照组(64例)。所有患者采用常规分割外照射放疗,试验组患者采用替莫唑胺化疗,对照组患者未进行化疗,比较两组患者近期疗效、中位无进展生存时间(PFS)及不良反应情况。结果试验组患者与对照组患者近期有效率分别为68.8%和40.6%,试验组高于对照组,差异有统计学意义(P<0.05)。两组患者头痛、呕吐、癫痫发作和白细胞减少等不良反应数据比较,差异均无统计学意义(均P>0.05)。试验组患者与对照组患者的中位PFS分别为61.2个月和54.6个月,试验组高于对照组,差异有统计学意义(P<0.05)。结论替莫唑胺治疗弥漫性低级别胶质瘤患者的效果显著,能够提高患者中位PFS。Objective To study the efficacy of temozolomide in the treatment diffuse low-grade gli- omas. Methods The clinical data of 96 patients with diffuse low-grade gliomas treated at Wuxi Second People＇s Hospital from January 2007 to September 2008 were retrospectively analyzed. According to whether temozolomide was managed postoperatively or after radiotherapy, patients were divided into an experimental group （32 patients） and a control group （64 patients）. All the patients underwent conventional fractionated external beam radiotherapy. Patients in the experimental group received temozolomide chemotherapy and pa- tients in the control group did not receive chemotherapy. Short-term efficacy, median progression-free sur- vival （PFS） and adverse reaction were compared between the two groups. Results P Short-term efficacy was higher in the experimental group （68. 8% ） than in the control group （40. 6% ） （P 〈0. 05）. There was no significant difference in headache, vomiting, seizures and leukopenia between the two groups （ P 〉 0. 05）. Median PFS was higher in the experimental group （61.2 months） than in the control group （54. 6 months ） （ P 〈 0. 05 ）. Conclusion Temozolomide shows significant efficacy which can improve the median PFS time in the treatment of diffuse low-grade gliomas in patients with diffuse low-grade gliomas. However, large samples are needed to confirm whether it can increase the overall survival.

关 键 词：替莫唑胺 弥漫性低级别胶质瘤 临床疗效 中位无进展生存时间 

分 类 号：R739.41[医药卫生—肿瘤]